Abstract:
Isoflavone compounds are described and recommended as therapeutic agents. Exemplified and preferred compounds are (a). Indications show compounds have good competitive binding to estrogen receptors. This is exemplified.
Abstract:
One embodiment of the present invention provides a system that facilitates accessing a credential. During operation, the system receives a request at a credentials-storage framework (CSF) to retrieve the credential. If a target credential store containing the credential is not already connected to the CSF, the system looks up a bootstrap credential for the target credential store in a bootstrap credential store, which contains bootstrap credentials for other credential stores. Next, the system uses this bootstrap credential to connect the CSF to the target credential store. Finally, the system retrieves the credential from the target credential store, and returns the credential to the requestor.
Abstract:
Systems, methods, and machine-readable media are disclosed for providing conditional grants of permission in an externally configured security policy. In one embodiment, a method is provided which comprises reading a condition clause from a grant statement defined in the security policy. The grant statement can cause the granting of permission for a user to access a requested resource. One or more constraints on the grant statement can be determined based on the condition clause. Permission can be granted to access the requested resource based on the one or more constraints.
Abstract:
The present invention relates to a bioenhancing/bioavailability-facilitating composition comprising: an effective amount of an extract and/or at least one bioactive fraction from Cuminum cyminum; one or more additive selected from drugs, nutrients, vitamins, nutraceuticals, herbal drugs/products, micro nutrients, antioxidants along with pharmaceutically acceptable additives/excipient, and optionally, an effective amount of piperine or extract/fraction of piper nigrum or piper longum; and a process for the preparation of such extracts and active fractions from plant Cuminum cyminum.
Abstract:
The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, carboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, hydrophobic, hydrophilic and fluorophilic alkyl derivatives and a polymers.
Abstract:
The present invention relates to the development of insulin resistant skeletal muscle cell culture model useful for the screening of compounds that enhance insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation required against type II diabetes.
Abstract:
A process of isolation of pure Acteoside of high hepatoprotection from plant Colerbrookea oppositifolia, said process comprising steps of drying aerial parts of the plant, grounding the dried parts into powder, percolating the powder with water or ethanol for 3-4 times to obtain an extract, filtering the extract for clearing of suspended particles to obtain supernatant, drying the supernatant at about 45 to 55° C. to obtain a residue, fractionating the residue with chloroform, ethyl acetate, and butanol successively, subjecting butanol fraction to adsorption chromatography of SiO2 after adding methanol to the fraction, charging the adsorbed fraction to glass column, eluting the column with solvents of increasing polarity of methanol:chloroform to obtain further fractions and repeating the process one more time, subjecting the fractions to column chromatography to obtain fractions, concentrating the fractions under reduced pressure to obtain acteoside as residue; and a method of effectively hepatoprotecting a subject using pure Acteoside from plant Colerbrookea oppositifolia, said method comprising steps of administering appropriate low-dose of the acteoside to the subject.
Abstract:
A method and apparatus for selectively accelerating network communications provides improved operation of network communications through channels with long delays, such as a satellite communications channel. A configuration management mechanism provides a selection of acceleration configuration for particular addresses of devices that may communicate through the communications channels. Acceleration may be bypassed for particular addresses or classes of devices within the network and priorities may be assigned, permitting a cut-off of acceleration when a threshold number of sessions is reached. The method and system may also allow a higher priority class of session to preempt lower priority session by removing resources from the lower priority session and assigning them to the higher priority session. The data rate of the lower priority session is then lowered (due to the absence of acceleration or reduced buffer size) to reduce traffic flow.
Abstract:
The present invention relates to a process for the preparation of trans-alkenoic acids of general formula CH3—(CH2)n—CH═(CH2)mCO2H where n=4 to 9 m=8 to 16. More particularly, the present invention relates to a process for the preparation of trans-tetracos-15-enoic acid, which is a bioactive constituent possessing dose-related hepatoprotective activity. The present invention also relates to the use thereof for hepatoprotection.